Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

INmune Bio gets US FDA nod for Phase II trial of Quellor, a sTNF inhibitor for COVID-19 treatment

expresspharmaSeptember 02, 2020

Tag: INmune Bio , TNF , Clinical Trial , Quellor

PharmaSources Customer Service